We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Varian Medical Hits 52-Week High; Oncology Prospects Bright
Read MoreHide Full Article
Share price of Varian Medical Systems Inc. rallied to a new 52-week high of $98.73 on Sep 22. This represents an impressive year-to-date return of approximately 21.9%, better than the S&P 500’s 6.5% over the same period.
Currently, Varian Medical has a Zacks Rank #3 (Hold). Notably, the stock has a market cap of $9.13 billion.
Key Factors
Varian’s oncology business growth prospects are impressive. The company is addressing both the tier 1 and mid-tier markets through its Edge, Truebeam and VitalBeam products. The company is also winning contracts, not only in the Americas but also in international markets, which is a huge positive.
Strong third-quarter 2016 results validate the company’s growth scenario. Adjusted earnings of $1.22 per share beat the Zacks Consensus Estimate by a nickel and increased 6.1% on a year-over-year basis. The figure comfortably surpassed management’s guided range of $1.16–$1.20 per share.
Oncology System sales increased 8.3% from the year-ago quarter to $605.2 million, while gross orders increased 6.4% to $675.9 million in the quarter. Moreover, Oncology gross margin improved more than 400 basis points to 46% driven by favorable product mix (higher mix of TrueBeams and software) as well as productivity gains.
Following robust results, Varian raised its fiscal 2016 guidance. The company now expects adjusted earnings in the range of $4.62–$4.66 per share, up from the previously guided range of $4.55–$4.65 per share. Revenues are still expected to increase 3% in fiscal 2016.
Estimate Revisions
The Zacks Consensus Estimate for fiscal 2016 increased by a penny to $4.65 over the last 30 days. For fiscal 2017, estimates have remained steady at $4.94 over the same time frame.
GW Pharmaceuticals consistently surpassed expectations in the last four quarters, with an average positive surprise of 41.67%. This represents an impressive year-to-date return of approximately 58.1%, better than the S&P 500’s 6.5% over the same period.
NuVasive also has a steady record in beating earnings expectations over the last four quarters, with an average positive surprise of 18.98%. This represents an impressive year-to-date return of approximately 25.78%, better than the S&P 500’s 6.5% over the same period.
Finally, Baxter International also surpassed expectations in each of the last four quarters, with an average positive surprise of 30.55%. This represents an impressive year-to-date return of approximately 26.34%, better than the S&P 500’s 6.5% over the same period.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Varian Medical Hits 52-Week High; Oncology Prospects Bright
Share price of Varian Medical Systems Inc. rallied to a new 52-week high of $98.73 on Sep 22. This represents an impressive year-to-date return of approximately 21.9%, better than the S&P 500’s 6.5% over the same period.
Currently, Varian Medical has a Zacks Rank #3 (Hold). Notably, the stock has a market cap of $9.13 billion.
Key Factors
Varian’s oncology business growth prospects are impressive. The company is addressing both the tier 1 and mid-tier markets through its Edge, Truebeam and VitalBeam products. The company is also winning contracts, not only in the Americas but also in international markets, which is a huge positive.
Strong third-quarter 2016 results validate the company’s growth scenario. Adjusted earnings of $1.22 per share beat the Zacks Consensus Estimate by a nickel and increased 6.1% on a year-over-year basis. The figure comfortably surpassed management’s guided range of $1.16–$1.20 per share.
VARIAN MEDICAL Price and Consensus
VARIAN MEDICAL Price and Consensus | VARIAN MEDICAL Quote
Oncology System sales increased 8.3% from the year-ago quarter to $605.2 million, while gross orders increased 6.4% to $675.9 million in the quarter. Moreover, Oncology gross margin improved more than 400 basis points to 46% driven by favorable product mix (higher mix of TrueBeams and software) as well as productivity gains.
Following robust results, Varian raised its fiscal 2016 guidance. The company now expects adjusted earnings in the range of $4.62–$4.66 per share, up from the previously guided range of $4.55–$4.65 per share. Revenues are still expected to increase 3% in fiscal 2016.
Estimate Revisions
The Zacks Consensus Estimate for fiscal 2016 increased by a penny to $4.65 over the last 30 days. For fiscal 2017, estimates have remained steady at $4.94 over the same time frame.
Key Sector Picks
Better-ranked stocks in the medical sector include GW Pharmaceuticals plc , NuVasive, Inc. and Baxter International Inc. (BAX - Free Report) . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
GW Pharmaceuticals consistently surpassed expectations in the last four quarters, with an average positive surprise of 41.67%. This represents an impressive year-to-date return of approximately 58.1%, better than the S&P 500’s 6.5% over the same period.
NuVasive also has a steady record in beating earnings expectations over the last four quarters, with an average positive surprise of 18.98%. This represents an impressive year-to-date return of approximately 25.78%, better than the S&P 500’s 6.5% over the same period.
Finally, Baxter International also surpassed expectations in each of the last four quarters, with an average positive surprise of 30.55%. This represents an impressive year-to-date return of approximately 26.34%, better than the S&P 500’s 6.5% over the same period.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>